|1.||Parkinson, Fiona E: 5 articles (12/2014 - 04/2006)|
|2.||Parker, William B: 5 articles (04/2008 - 11/2003)|
|3.||Long, Mary C: 5 articles (04/2008 - 11/2003)|
|4.||Jarvis, M F: 5 articles (06/2001 - 03/2000)|
|5.||Jackson, Edwin K: 4 articles (09/2015 - 06/2009)|
|6.||Colgan, Sean P: 4 articles (02/2013 - 12/2005)|
|7.||Zamzow, Christina R: 4 articles (10/2009 - 04/2006)|
|8.||Kowaluk, E A: 4 articles (06/2001 - 03/2000)|
|9.||Vijayalakshmi, I B: 3 articles (11/2015 - 02/2013)|
|10.||Xiong, Wei: 3 articles (12/2014 - 09/2008)|
11/01/1993 - "Ado infusion improved recovery of mechanical function after hypothermic ischemia, and its beneficial effect appears to involve both A1 and A2 receptors. "
11/01/1996 - "They also show that the metabolic and protective effects of Ado depend on the status of the heart before sustained ischemia."
07/01/2001 - "Administration of ADO or SNP on day 1 without IPC produced a similar microvascular protection against prolonged ischemia/reperfusion on day 2 as that induced by IPC alone. "
01/01/1996 - "The aim of this study was to investigate whether there was a concentration-response between the administration of ADO prior to ischemia-reperfusion and reduction in subsequent infarct size. "
12/20/2014 - "In the subgroup analysis, among patients with ischemia time below 200 min, the increase in LVEF was slightly higher with ADO (3.59% vs. 0.43%; p for interaction=0.06). "
|2.||Patent Ductus Arteriosus
08/01/2013 - "To evaluate safety and efficacy of closure of patent ductus arteriosus (PDA) with Amplatzer duct occluder II Additional Sizes (ADO II AS) and to report early and midterm results of the device in children and very young symptomatic infants. "
09/01/2005 - "The Amplatzer duct occluder (ADO) provides a safe and effective therapy for patients with moderate- to large-sized patent ductus arteriosus (PDA), but there have been few reports of transcatheter closure of very large PDAs in young children and infants. "
06/01/2012 - "The objective of this study was to evaluate the technical feasibility, safety, and efficacy of the new device Amplatzer duct occluder II additional sizes (ADO II AS) for closure of patent ductus arteriosus (PDA). "
01/01/2001 - "The aim of the study was to assess the safety and efficacy of the Amplatzer ductal occluder (ADO) in transcatheter occlusion of patent ductus arteriosus (PDA). "
07/15/2004 - "This study compared the efficacy and costs of the most used approaches for percutaneous closure of large patent ductus arteriosus, that is, multiple coils and the Amplatzer duct occluder (ADO) device. "
|3.||Breast Neoplasms (Breast Cancer)
07/02/2015 - "There was weaker evidence for iCHAV4, located 5' of ADO, associated only with ER-positive breast cancer (OR = 0.93 [0.90-0.96]). "
04/01/2015 - "Breast cancer axillary staging: much ado about micrometastatic disease."
12/01/2010 - "An appraisal of pre-operative MRI in breast cancer: more effective staging of the breast or much ado about nothing?"
04/01/1989 - "Breast cancer screening: all's well that ends well, or much ado about nothing?"
10/01/1988 - "Breast cancer screening: all's well that ends well, or much ado about nothing?"
|4.||Dyspnea (Shortness of Breath)
05/01/2014 - "All CODEX C statistics were superior to those of the BODEX, DOSE (dyspnea, airfl ow obstruction, smoking status, and exacerbation frequency), and updated ADO (age, dyspnea, and airfl ow obstruction) indexes. "
01/01/2014 - "Furthermore, the effects of pulmonary function, ADO index (age, dyspnea, and airflow obstruction) and modified BODE index (body mass index, airflow obstruction, dyspnea, and exercise capacity) on the PA were evaluated. "
02/01/2013 - "The MMRC dyspnea grade, PASE score, ADO index and SBAS score were associated with SPI, but general self-efficacy and spirometry were not. "
02/01/2013 - "Logistic models were generated including the modified Medical Research Council (MMRC) dyspnea grade, spirometry and the age-dyspnea-airflow obstruction (ADO) index. "
01/01/2013 - "To determine which of three multidimensional assessment systems (the body mass index, obstruction, dyspnea, and exercise capacity [BODE] index; dyspnea, obstruction, smoking, exacerbations [DOSE] index; or age, dyspnea, obstruction [ADO] index) is superior for predicting exacerbations. "
|5.||Ventricular Heart Septal Defects (Ventricular Septal Defect)
04/01/2015 - "The purpose of this study was to show that transcatheter closure of perimembranous ventricular septal defect with Amplatzer Ductal Occluder (ADO) is an effective and safe method. "
12/01/2013 - "To show that transcatheter closure of perimembranous ventricular septal defect (PMVSD) with the Amplatzer ductal occluder (ADO, AGA Medical Corp, Plymouth, Minnesota) is a safe and effective treatment option. "
10/01/2015 - "Main aim of our study to show that ADO II device can be used for the small ventricular septal defects successfully and safely with low complication rates in pediatric population. "
02/01/2011 - "To describe the technique and results of transcatheter closure of ventricular septal defects (VSDs) by a modified retrograde transarterial approach using the new Amplatzer Duct Occluder II (ADO II). "
10/01/2015 - "Considering perimembraneous ventricular septal defects as difficult and risky for percutaneous closure because of its proximity to aortic, atrioventricular valves and conduction tissue, we suggest that ADO II device can be safely and effectively used for such defects in particular if an aneurysm formation is present which is also compatible with the literature. "
|4.||Purinergic P1 Receptors (Adenosine Receptor)
|5.||Proton Pump Inhibitors
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|10.||Aspartate Aminotransferases (Aspartate Transaminase)
|1.||Induced Heart Arrest (Cardioplegia)